BIOSENSORS REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER OF FISCAL YEAR 2013

Financial Performance and Recent Highlights:

 In January, Biosensors received CE Mark approval for its polymer-free drug-coated stent (DCS), BioFreedom™ the Company has also commenced global patient enrollment for LEADERS FREE clinical study during the quarter

 Biosensors has signed an OEM agreement for both coronary and peripheral drug-eluting balloons which will be marketed under Biosensors’ brand name. These products have obtained several regulatory approvals including CE mark and will be available to Biosensors for worldwide distribution

 Recently, the Company successfully raised S$300 million (approximately US$240 million) from the issuance of 4.875% fixed rate notes due 2017 under its S$800 million Multicurrency Medium Term Note Programme

 In Q3 FY13, Interventional Cardiology Products (
IVP) sales, largely comprising drug-eluting stent (DES) sales, increased by 9% year-on-year. For the FY13 nine-month period, IVP sales grew 42% compared to the same period last year

 Total revenue for the FY13 nine-month period increased 21% over the same period last year; in Q3 FY13, total revenue declined by 4% year-on-year due to lower royalty and licensing revenue

 In Q3 FY13, gross margin on total product sales was 82%, improved from previous quarter’s 80% and 70% in the same quarter last year

Financial Guidance for FY13

Year-to-date, the Company has achieved healthy growth in its product sales, in line with the original target. However, due to changes in the dynamics of the Japanese market, including regulatory imposition and new products from competitors, licensing revenue from Terumo Corporation (
Terumo) for the sales of the Nobori DES was adversely affected in the first nine months of the fiscal year. As such, management is adjusting its guidance for total revenue for the fiscal year ending 31 March 2013 (FY13) to a 15% to 20% growth over FY12, driven by continued strong DES revenue growth in the key markets managed by the Company, but offset by a decrease in licensing revenue.

"We will leverage our experience in the international markets, along with the positive clinical results we achieved, to work closely with Terumo to strengthen Nobori’s competitive position in Japan, aiming at increasing the product’s market share and our royalty revenue. In China, we have seen that the tendering process has accelerated, which will inevitably create some short-term disruptions. However, this will remove the overhanging uncertainty on the future of this important market. At the same time, we will also introduce new products to improve our overall sales revenue in China. For the rest of the world, we continued to perform well in Europe and Asia Pacific, with strong year-on-year growth outpacing the market," said Dr. Wang. "During the quarter, we successfully raised approximately US$240 million from the bond offering. Coupled with our existing financial resources, we accumulated more than US$570 million of cash and cash equivalents. We are in various stages of discussions with several potential M&A targets, some of these discussions being near completion. We believe these possible transactions, once concluded, can further expand our product offering. Such efforts can substantially increase our shareholder value and take Biosensors to the next level."